Indian IPO Blog: Eris Lifesciences IPO
Showing posts with label Eris Lifesciences IPO. Show all posts
Showing posts with label Eris Lifesciences IPO. Show all posts

Sunday, June 25, 2017

Tentative Listing Dates of IPOs in June 2017

June 25, 2017 0
Tentative Listing Dates of IPOs in June 2017
Tentative Listing dates of IPOs in June 2017

Tejas Networks IPO
27th June – Listing on NSE & BSE

Eris LifeSciences IPO
29th June – Listing on NSE & BSE

CDSL IPO
30th June – Listing on NSE only

AU Financiers (Small Bank) IPO
07th July – Listing on NSE & BSE

GTPL IPO
03rd July – Listing on NSE & BSE

Saturday, June 24, 2017

Eris Lifesciences IPO Allotment Status declared

June 24, 2017 0
Eris Lifesciences IPO Allotment Status declared

Eris Lifesciences IPO Allotment Status is  declared and can be checked from link given below :

Check out the link given below to check Eris Lifesciences IPO Allotment Status! 

https://linkintime.co.in/PublicIssues/

Eris Lifesciences IPO Final Subscription Status

June 24, 2017 0
Eris Lifesciences IPO Final Subscription Status

Monday, June 12, 2017

Eris Lifesciences IPO Price Band and Details

June 12, 2017 0
Eris Lifesciences IPO Price Band and Details

Issue opens on: Jun 16, 2017
Issue closes on: Jun 20, 2017
Issue size: 28,875,000 Equity Shares of Rs.1 each
Price Band: Rs.600 to Rs.603 per equity shares
Bid Lot: 24 Equity Shares and in multiples thereof

Thursday, June 8, 2017

Eris Lifesciences IPO opens on June 16

June 08, 2017 0
Eris Lifesciences IPO opens on June 16

Eris Lifesciences Limited is planning to hit the streets with an IPO which would be open for subscription between June 16, 2017 and June 20, 2017

Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.

Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.

Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics)

The objects of the Offer are:
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and 
2. For the sale of up to 28,875,000 Equity Shares by the Selling Shareholders.

Saturday, February 11, 2017

Eris Lifesciences files DRHP for IPO

February 11, 2017 0
Eris Lifesciences files DRHP for IPO
Eris Lifesciences Pvt. Ltd filed a draft red herring prospectus with the capital markets regulator Securities and Exchange Board of India (SEBI) for an initial public offering (IPO) on Wednesday.

The IPO comprises an offer for sale (OFS) by the drug company’s private equity backer ChrysCapital and some of the founding shareholders.

Eris Lifesciences is the first pharmaceutical company to file its draft papers this year. The last pharmaceutical firm to go public was Warburg Pincus-backed Laurus Labs in November 2016. Before that, Alkem Laboratories went public in January 2016.